| Business Summary | | Genome
Therapeutics
Corp.
is
engaged
in
the
commercialization
of
genomics-based
drug
discovery.
Through
the
identification
of
genes
and
the
characterization
of
the
function
of
those
genes,
the
Company
is
seeking
to
accelerate
the
discovery
and
development
of
products
to
treat
and
diagnose
a
number
of
diseases.
The
United
States
government
has
selected
the
Company
to
participate
in
a
number
of
government
sponsored
gene
discovery
programs,
including
the
Human
Genome
Project,
and
the
Rat
Genome
Sequencing
Program.
The
Company's
depth
of
experience
in
the
genomics
field
permits
it
to
be
a
leader
in
creating
industrial
scale
genomics
tools
for
product
development.
Its
tools
include
high-throughput
sequencing,
sequence
finishing,
bioinformatics,
functional
genomics,
and
assay
development. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | Genome
Therapeutics
Corporation
is
a
genomics-based
drug
target
discovery
company
focusing
on
the
discovery
and
characterization
of
novel
targets
in
pathogens
that
are
responsible
for
many
serious
human
diseases.
For
the
39
weeks
ended
5/26/01,
revenues
fell
1%
to
$20.2
million.
Net
loss
totalled
$4.7
million,
up
from
$1.1
million.
Results
reflect
a
reduction
in
contract
research
revenue
and
lower
milestone
payments,
and
higher
costs
related
to
the
internal
research
programs. | More
from
Market Guide: Significant
Developments |
| | | | FY2000
Compensation | | Pay | Exer | |
| Robert Hennessey, 59 Chairman | $446K | $14.7M | Stephen Rauscher, 47 Pres,
CEO, Director | -- | -- | Stephen Cohen CFO,
Sr. VP | -- | -- | Christopher Kelly, 47 Sr.
VP and Gen. Mang. -- Drug Rescue | 222K | 2.2M | Richard Labaudiniere, Ph.D Sr.
VP, of R&D | -- | -- | Dollar
amounts are as of 31-Aug-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.; "Exer" is the value of options excercised during the fiscal year. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|